Analyst Ratings For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Today, Argus raised its price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $175.00 per share.
There are 3 hold ratings, 21 buy ratings on the stock.
The current consensus rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is Buy (Score: 2.88) with a consensus target price of $162.41 per share, a potential 6.97% upside.
Some recent analyst ratings include
- 7/27/2017-BMO Capital Markets Reiterated Rating of Outperform.
- 7/22/2017-Morgan Stanley Reiterated Rating of Overweight.
- 7/21/2017-Robert W. Baird Reiterated Rating of Outperform.
Recent Insider Trading Activity For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has insider ownership of 1.80% and institutional ownership of 94.37%.
- On 7/21/2017 Amit Sachdev, EVP, sold 28,625 with an average share price of $160.93 per share and the total transaction amounting to $4,606,621.25. View SEC Filing
- On 7/21/2017 Ian F Smith, CFO, sold 133,750 with an average share price of $160.98 per share and the total transaction amounting to $21,531,075.00. View SEC Filing
- On 7/21/2017 Jeffrey Chodakewitz, CMO, sold 46,733 with an average share price of $160.96 per share and the total transaction amounting to $7,522,143.68. View SEC Filing
- On 7/21/2017 Jeffrey M Leiden, CEO, sold 216,624 with an average share price of $160.96 per share and the total transaction amounting to $34,867,799.04. View SEC Filing
- On 7/21/2017 Paul M Silva, SVP, sold 43,443 with an average share price of $161.07 per share and the total transaction amounting to $6,997,364.01. View SEC Filing
- On 7/19/2017 Michael Parini, EVP, sold 10,829 with an average share price of $161.00 per share and the total transaction amounting to $1,743,469.00. View SEC Filing
- On 7/17/2017 Jeffrey Chodakewitz, CMO, sold 573 with an average share price of $129.85 per share and the total transaction amounting to $74,404.05. View SEC Filing
Recent Trading Activity for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Shares of Vertex Pharmaceuticals Incorporated closed the previous trading session at 150.84 down -0.99 -0.65% with 2,975,961 shares trading hands.